Prostate Cancer - Results from #620

Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer. July 10, 2024

Fluorine-18 Prostate-Specific Membrane Antigen–1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer July 9, 2024

Circulating Tumor Extracellular Vesicles to Monitor Metastatic Prostate Cancer Genomics and Transcriptomic Evolution July 9, 2024

Molecular and diffusion features for identification of clinically significant prostate cancer in PI-RADS 3 lesions. July 9, 2024

A case-cohort study of per- and polyfluoroalkyl substance concentrations and incident prostate cancer in the Cancer Prevention Study-II LifeLink Cohort study. July 9, 2024

Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial. July 9, 2024

Use of Decipher Prostate Biopsy Test in Patients with Favorable-risk Disease Undergoing Conservative Management or Radical Prostatectomy in the Surveillance, Epidemiology, and End Results Registry. July 9, 2024

Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study. July 9, 2024

Early Prostate Cancer Deaths Among Men With Higher vs Lower Genetic Risk. July 9, 2024

Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. July 9, 2024

shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer. July 9, 2024

Predicting prostate cancer grade reclassification on active surveillance using a deep Learning-Based grading algorithm. July 9, 2024

Clonal Lineage Tracing with Somatic Delivery of Recordable Barcodes Reveals Migration Histories of Metastatic Prostate Cancer. July 8, 2024

MCTP1 increases the malignancy of androgen-deprived prostate cancer cells by inducing neuroendocrine differentiation and EMT. July 8, 2024

Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models. July 8, 2024

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. July 8, 2024

Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial. July 8, 2024

PSA Stratification for Predicting Advanced Prostate Cancer Events in Men Approaching Age-Limits for Recommended Screening. July 8, 2024

Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies. July 8, 2024

Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study. July 8, 2024

Page 32 of 1436